EXAS (EXAS)

$104.91
+0.00%
Market Cap
P/E Ratio
Beta
Dividend Yield
Piotroski 6/9Beneish M -2.86 Clean

Quantitative Summary

Deterministic

Financial health is average: Piotroski 6/9. DCF fair value of $59 implies 44% downside based on model assumptions.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The underlying economic engine presents a stark dichotomy between robust top-line expansion and deteriorating bottom-line efficiency. While revenue grows at 17.7% annually, the company generates negative operating leverage with a net margin of -6.4%, driving an ROIC spread that is deeply negative relative to capital costs. This erosion in profitability is mathematically evident in the DuPont decomposition: despite healthy asset turnover (0.55x) and moderate financial leverage (2.44x), the collapse in margins drags overall return on equity down to -8.7%. Although the Piotroski F-Score of 6/9 suggests reasonable operational stability, the Beneish M-Score of -2.86 indicates a low probability of earnings manipulation, yet it cannot offset the fundamental reality that current operations are destroying value rather than generating cash flow.

Valuation metrics reflect this disconnect between growth expectations and realized returns. The stock trades at a significant discount to its DCF-derived fair value of $59, implying roughly 43.9% downside from current levels if the model's assumptions hold true. This pricing gap stems largely from market skepticism regarding the sustainability of such high implied free cash flow growth (22.0% over ten years) in an environment where net margins remain deeply negative. The asset is currently priced with a distinct tilt toward future growth potential, evidenced by a Value Factor (HML) of -0.682 and weak Profitability Factor (RMW) scores at -0.144, suggesting the market has not yet fully discounted the risk that current profitability trends may persist or worsen before they improve.

Risk-adjusted performance data reveals significant divergence between raw alpha generation and factor-based consistency. The Fama-French Alpha stands at an impressive 18.35% annually, indicating strong outperformance relative to a standard benchmark over the measured period; however, this comes with notable exposure to specific risk factors. Specifically, the negative Value Factor score highlights that returns are being driven by growth characteristics rather than value premiums, while the weak Profitability Factor underscores the vulnerability of the firm's earnings quality. With insider flow remaining neutral at zero over the last 90 days, there is no clear signal from management regarding future capital allocation or confidence in turning the profitability tide, leaving investors to weigh high theoretical alpha against structural margin constraints and valuation headwinds.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive
Reverse DCFMarket-Implied
22.0%annual FCF growth priced in at $104.91

The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 18% YoY revenue.

Sensitivity Matrix

TG ↓ / WACC →8%10%12%
2%$74$52$39
3%$88$59$43
4%$109$68$48

Center = base case. Green = >10% upside, Red = >10% downside vs $104.91.

Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $59 (-43.9%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Technical Setup

AI Generated

The current trading price of $104.91 for EXAS presents a technical snapshot that requires further context regarding its relationship to key moving averages, which are not provided in the available data set. Without knowing whether this level sits above or below short-term and long-term trend lines such as the 50-day or 200-day simple moving average, it is impossible to definitively characterize the prevailing momentum direction or identify if the asset is in an established uptrend or downtrend phase. The absence of these comparative metrics limits the ability to assess whether recent price action represents a continuation of historical trends or a potential reversal point based on standard trend-following methodologies. Regarding short-term momentum, the Relative Strength Index (RSI) data is also missing from the current information, preventing an evaluation of overbought or oversold conditions. Typically, RSI values above 70 might suggest extended upward pressure where correction risks are often monitored by analysts, while readings below 30 could indicate potential buying opportunities following a decline. Since these specific indicators are unavailable for EXAS at $104.91, no conclusion can be drawn about the immediate velocity of price movement or the strength behind recent gains and losses. To form a complete technical picture, additional data points regarding moving average crossovers and RSI levels would be necessary to synthesize a comprehensive view of market sentiment. Until such information is available, observers should note that the current price level exists in isolation from its

RSI (14)
SMA 50
SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
-2.86
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

69.7%
Gross Margin
-6.4%
Net Margin
-2.6%
ROIC
+17.7%
Revenue Growth (YoY)
+79.8%
Earnings Growth (YoY)
356.8M
Free Cash Flow

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

-6.4%
Net Profit Margin
NI ÷ Revenue
×
0.55x
Asset Turnover
Revenue ÷ Assets
×
2.44x
Equity Multiplier
Assets ÷ Equity
=
-8.7%
Return on Equity
Balanced ROE composition across margins, turnover, and leverage.

Balance Sheet Health

1.44x
Debt / Equity
2.43x
Current Ratio
-4.9x
Interest Coverage
26.1x
Net Debt / EBITDA
52.4M
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $-0.10
Act: $-0.36
-276.9%
Q3
✓ Beat
Est: $0.05
Act: $0.10
+84.9%
Q2
✓ Beat
Est: $0.16
Act: $0.24
+49.4%
Q1
✗ Miss
Est: $0.08
Act: $-0.21
-378.3%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Risk Profile

54.5%
Annual Volatility
2.05
Sharpe (1Y)
0.46
Sharpe (3Y)
-59.3%
Max Drawdown (3Y)
-78.2%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

0.60
Market β
Mkt-RF
+0.663
Size (SMB)
Small-cap tilt
-0.682
Value (HML)
Growth tilt
-0.144
Profit (RMW)
Weak
+0.052
Invest (CMA)
Neutral
Alpha (annual): +18.35%
R²: 10.1%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

Forward P/E
PEG Ratio
Price/Book
Avg Volume
52W High
52W Low
52W Range Position

EXAS Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
EXAS
PRICE
$104.91
FLOOR (POC)
$100.02
STRENGTH
High
$40$449%$478%$50$5415%$578%$60$64$67$70$74$77$80$83$87$90$93$97$100POC 23%$10319%$104.91
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for EXAS over the past year sits near $100.02 (23% of 252-day volume). The current price of $104.91 trades 4.9% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (23% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

EXAS Capital Efficiency

How efficiently does EXAS convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$357M
EBITDA
$52M
FCF Conversion
680%
Reinvestment Rate
-580%
680% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)

EXAS converts 680% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-03-242,099$104.91$220,206.09
2026-03-236,494$104.91$681,285.54
2026-03-0355,749$103.35$5.8M
2026-02-1320,470$103.23$2.1M
2026-01-204,513$102.43$462,266.59
2026-01-1637$102.34$3,786.58
2026-01-151,446$102.26$147,867.96
2026-01-14508$102.25$51,943
2026-01-093$101.78$305.34
2025-12-304,813$101.93$490,589.09
2025-12-23557,190$101.82$56.7M
2025-12-1634$101.74$3,459.16
2025-12-0467$101.25$6,783.75
2025-12-032,309$101.20$233,670.8
2025-12-02209$101.20$21,150.8
2025-11-269,100$101.13$920,283
2025-11-241,186$100.90$119,667.4
2025-11-2119,786$100.67$2.0M
2025-11-20278$86.18$23,958.04
2025-11-17100$67.03$6,703
2025-11-1433,779$67.75$2.3M
2025-11-129,076$67.50$612,630
2025-11-10100$66.18$6,618
2025-11-0613,471$69.63$937,985.73
2025-11-03100$64.69$6,469
2025-10-28242$63.50$15,367
2025-10-2211,877$63.41$753,120.57
2025-10-201,628$61.23$99,682.44
2025-10-14105,705$59.36$6.3M
2025-10-10195$59.46$11,594.7

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
ADPT0.3530.328Moderate
GEHC0.3200.222Moderate
MTD0.3160.152Moderate
ISRG0.3130.090Moderate
A0.3100.152Moderate
NRIX0.3040.271Moderate
NTRA0.3020.205Moderate
CPT0.3020.118Moderate
TXG0.2990.124Low correlation

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare EXAS to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-03-23.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.